Peregrine Pharmaceut
Peregrine Pharmaceuticals to Participate in Two Upcoming Life Science Investor Conferences
November 23, 2015 08:05 ET | Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...
AstraZeneca and Pere
AstraZeneca and Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration to Include Phase II Lung Cancer Combination Clinical Trial
October 15, 2015 08:05 ET | Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...
Michael-Weyant_DoubleLungLiverTransplant_035 (1)
University of Colorado Hospital Announces new Center for Lungs and Breathing
October 01, 2015 09:05 ET | UCHealth
AURORA, COLO., Oct. 1, 2015 (GLOBE NEWSWIRE) -- UCHealth's University of Colorado Hospital (UCH), a national leader in pulmonology, cancer and upper airway disorders, opens its new multidisciplinary...
Peregrine Pharmaceut
Peregrine Pharmaceuticals Declares Quarterly Dividend On Its Series E Convertible Preferred Stock
September 08, 2015 16:05 ET | Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 08, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...
New Translational Da
New Translational Data Highlights Bavituximab’s Ability to Induce Signs of Immune Activation in Lung Cancer Tumor Samples With Negative PD-L1 Expression
September 08, 2015 08:05 ET | Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 08, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...
Peregrine to Report
Peregrine to Report Financial Results for First Quarter of Fiscal Year 2016 After Market Close on September 9, 2015
September 03, 2015 16:05 ET | Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 03, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...
Peregrine Pharmaceut
Peregrine Pharmaceuticals Presents Data at Annual Immunotherapy and Vaccine Summit (ImVacS) Supporting Ability of Bavituximab to Mediate Anti-Tumor T Cell Responses Across Multiple Tumor Types
August 26, 2015 09:00 ET | Peregrine Pharmaceuticals Inc.
- Increasing Activated T Cells in Tumors Demonstrates Potential Complement to anti-PD-1 and anti-PD-L1 Checkpoint Inhibitors - - Clinical and Preclinical Studies Demonstrate Estimated Survival...
OncoMed Pharmaceuticals, Inc. Logo
OncoMed Presents Data From Phase 1b Trial of Demcizumab in Pancreatic Cancer at the 2015 ASCO Annual Meeting
June 01, 2015 09:00 ET | OncoMed Pharmaceuticals, Inc.
Demcizumab plus Abraxane and Gemcitabine in Advanced Pancreatic Cancer Results in 50% Response Rate, Progression-Free Survival of 9.0 Months and Overall Survival of 10.1 Months Randomized Phase 2...
Patient Advocate Foundation logo
Patient Advocate Foundation Receives Donation to Benefit Patients Through New Program
March 31, 2015 06:34 ET | Patient Advocate Foundation
HAMPTON, VA., March 31, 2015 (GLOBE NEWSWIRE) -- Patient Advocate Foundation (PAF) is pleased to announce the receipt of funding to support the addition of a new transportation-focused program within...
Qu Biologics Enrolls First Two Participants in Phase 2a Clinical Trial for Lung Cancer
February 04, 2015 10:05 ET | Qu Biologics;BC Cancer Agency
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 4, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body's...